3 Works

Data from: Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

Frederik Barkhof, Ludwig Kappos, Jerry S. Wolinsky, David K. B. Li, Amit Bar-Or, Hans-Peter Hartung, Shibeshih Belachew, Jian Han, Laura Julian, Annette Sauter, Julie Napieralski, Harold Koendgen & Stephen L. Hauser
Objective: To assess the onset of ocrelizumab efficacy on brain magnetic resonance imaging (MRI) measures of disease activity in the Phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse rate in the pooled Phase III studies in relapsing multiple sclerosis (RMS). Methods: Brain MRI activity was determined in the Phase II trial at monthly intervals in patients with RRMS receiving placebo, ocrelizumab (600 mg), or intramuscular interferon (IFN) β-1a (30 μg). Annualized relapse rate...

Data from: Large scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine

Gerrit L.J. Onderwater, Lannie Ligthart, Mariska Bot, Ayse Demirkan, Jingyuan Fu, Carla J.H. Van Der Kallen, Lisanne S. Vijfhuizen, René Pool, Jun Liu, Floris H.M. Vanmolkot, Marian Beekman, Hoyan Wen, Najaf Amin, Carisha S. Thesing, Judith A. Pijpers, Dennis A. Kies, Ronald Zielman, Irene De Boer, Marleen M.J. Van Greevenbroek, Ilja C.W. Arts, Yuri Milaneschi, Miranda T. Schram, Pieter C. Dagnelie, Lude Franke, M. Arfan Ikram … & Arn M.J.M. Van Den Maagdenberg
Objective: To identify a plasma metabolomic biomarker signature for migraine. Methods: Plasma samples from 8 Dutch cohorts (n = 10,153: 2,800 migraine patients and 7,353 controls) were profiled on a 1H-NMR-based metabolomics platform, to quantify 146 individual metabolites (e.g., lipids, fatty acids, and lipoproteins) and 79 metabolite ratios. Metabolite measures associated with migraine were obtained after single-metabolite logistic regression combined with a random-effects meta-analysis performed in a nonstratified and sex-stratified manner. Next, a global test...

Data from: Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia

Laurent M. A. Favié, Floris Groenendaal, Marcel P. H. Van Den Broek, Carin M. A. Rademaker, Timo R. De Haan, Henrica L. M. Van Straaten, Peter H. Dijk, Arno Van Heijst, Jeroen Dudink, Koen P. Dijkman, Monique Rijken, Inge A. Zonnenberg, Filip Cools, Alexandra Zecic, Johanna H. Van Der Lee, Debbie H. G. M. Nuytemans, Frank Van Bel, Toine C. G. Egberts & Alwin J. R. Huitema
Objective: Morphine is a commonly used drug in encephalopathic neonates treated with therapeutic hypothermia after perinatal asphyxia. Pharmacokinetics and optimal dosing of morphine in this population are largely unknown. The objective of this study was to describe pharmacokinetics of morphine and its metabolites morphine-3-glucuronide and morphine-6-glucuronide in encephalopathic neonates treated with therapeutic hypothermia and to develop pharmacokinetics based dosing guidelines for this population. Study design: Term and near-term encephalopathic neonates treated with therapeutic hypothermia and...

Registration Year

  • 2019

Resource Types

  • Dataset


  • VU University Medical Center
  • University Medical Center Groningen
  • Vrije Universiteit Brussel
  • VU University Amsterdam
  • Emma Kinderziekenhuis
  • Erasmus University Medical Center
  • Amsterdam Neuroscience
  • Leiden University
  • Maastricht University Medical Centre
  • University College London